Skip to main content

Advertisement

SpringerLink
Log in

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Raloxifene, a nonsteroidal selective estrogen receptor modulator (SERM), increases bone mineral density (BMD), decreases biochemical markers of bone turnover, and prevents incident vertebral fractures in postmenopausal women, while sparing the breast and endometrium from the undesirable stimulation caused by estrogen. How the long-term beneficial effects of raloxifene on bone turnover, as assessed by bone histomorphometry, compare with hormone replacement therapy (HRT) and placebo are not known. We studied 66 healthy postmenopausal women (age 55 to 75 years, mean 63 years) who were randomized to either raloxifene 150 mg/day, HRT (Premarin 0.625 mg/day, and Provera 2.5 mg/day), or placebo for 1 year. All women received 1–1.5 g of calcium/day. Following double tetracycline labeling, transiliac bone biopsies were obtained at baseline and 1 year and analyzed for changes in histologic indexes of bone remodeling on the cancellous surface as well as at the endocortical subdivision of the endosteal envelope, the location of the greatest fraction of postmenopausal bone loss. BMD and biochemical markers of bone turnover were also determined at baseline and 1 year. Four paired biopsies were obtained in the HRT group, six in the raloxifene group, and five in the placebo group. The frequency of remodeling events on cancellous bone and rate of bone formation in both cancellous and endocortical bone increased in the placebo group, while these measurements decreased in both drug treatment groups. Using analysis of mean percentage changes, when compared with the placebo group, these changes were significantly different for both raloxifene and HRT treatment groups (p<0.02). In all subjects, the bone was lamellar with discrete tetracycline labels and there was no evidence of marrow fibrosis or abnormal bone cells. BMD increased from baseline at the lumbar spine (p<0.05 in the HRT group) and in the total body (p<0.05 for both raloxifene and HRT). Compared with that of the raloxifene group, the increase in BMD was greater in the HRT group at the lumbar spine but not in the total body. Serum bone alkaline phosphatase, serum osteocalcin, and urine C-terminal cross-linking telopeptide of type I collagen significantly decreased (p<0.05) in both active treatment groups, changes significantly different from those seen with placebo. Overall, these results support the hypothesis that raloxifene preserves bone mass by reducing the elevated bone turnover found in postmenopausal women receiving placebo, by mechanisms similar to those operative in postmenopausal women receiving HRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1. A
Fig. 2.

Similar content being viewed by others

References

  1. Grady D, Hulley SB (2000) Editorial: hormones to prevent coronary heart disease in women; when are observational studies adequate evidence? Ann Intern Med 133:999–1001

    PubMed  Google Scholar 

  2. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288(3):321–333

    Google Scholar 

  3. Grant C, Gray A, Paoletti R et al (1999) Clinical synthesis conference: hormone replacement therapy. Lancet 354:152–155

    PubMed  Google Scholar 

  4. Mitlak BH, Cohen FJ (1999) Selective estrogen receptor modulators: a look ahead. Drugs 57:653–663

    CAS  PubMed  Google Scholar 

  5. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1641–1647

    Google Scholar 

  6. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE). JAMA 282:637–645

    CAS  PubMed  Google Scholar 

  7. Prestwood KM, Gunness M, Wong M, Lu Y, Muchmore D, Raisz L (2000) A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 85:2197–2202

    Google Scholar 

  8. Keshawarz NM, Recker RR (1984) Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab Bone Dis Rel Res 5:223–228

    CAS  Google Scholar 

  9. Brown JB, Delmas PD, Arlot M, Meunier PJ (1987) Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 64:654–659

    Google Scholar 

  10. Weinstein RS, Bell NH (1988) Diminished rates of bone formation in normal black adults. N Engl J Med 319:1698–1701

    CAS  PubMed  Google Scholar 

  11. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610

    CAS  PubMed  Google Scholar 

  12. Arlot ME, Delmas PD, Chappard D, Meunier PJ (1990) Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporos Int 1:41–49

    CAS  PubMed  Google Scholar 

  13. Riggs BL, Khosla S, Melton LJ (1998) A unitary model for involutional osteoporosis; estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 12:763–773

    Google Scholar 

  14. Weinstein RS, Manolagas SC (2000) Apoptosis and osteoporosis. Am J Med 108:153–164

    CAS  PubMed  Google Scholar 

  15. Parfitt AM (1992) The two-stage concept of bone loss revisited. Triangle 31:99–110

    Google Scholar 

  16. Balena R, Shih M-S, Parfitt AM (1992) Bone resorption and formation on the periosteal envelope of the ilium; a histomorphometric study in healthy women. J Bone Miner Res 7:1475–1482

    CAS  PubMed  Google Scholar 

  17. Shih M-S, Cook MA, Spence CA, Palnitkar S, McElroy H, Parfitt AM (1993) Relationship between bone formation rate and osteoblast surface on different subdivisions of the endosteal envelope in aging and osteoporosis. Bone 14:519–521

    CAS  PubMed  Google Scholar 

  18. Han Z-H, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 12:498–508

    CAS  PubMed  Google Scholar 

  19. Reid I, Fogelman I, Eastell R, Sarkar S, Wu W, Ciaccia A, Draper M (2000) Impact of hysterectomy in studies of raloxifene in healthy and osteoporotic postmenopausal women [abstract]. In: 11th international congress of endocrinology abstract book, Sydney, Australia, 29 October–2 November, 2000 (Abstract P340)

  20. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates J, Lombardi A (1999) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 85:720–726

    Google Scholar 

  21. Vedi S, Compston JE (1996) The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women. Bone 19:535–539

    CAS  PubMed  Google Scholar 

  22. Johnson CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H, Gennari C, Christiansen C, Arnaud CD, Delmas PD (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med 160:3444–3450

    Article  CAS  PubMed  Google Scholar 

  23. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 10:330–336

    CAS  PubMed  Google Scholar 

  24. Agnusdei D, Iori N (2000) Raloxifene: results from the MORE study. J Musculoskel Neuron Interact 1:127–132

    CAS  Google Scholar 

  25. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL (1998) Treatment of established postmenopausal with raloxifene: a randomized trial. J Bone Miner Res 13:1747–1754

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are indebted to Frances Swain, Julie Crawford, Carman Young, Tony Chambers, and William Webb for excellent technical assistance.

Author information

Author notes

  1. Robert Marcus

    Present address: Eli Lilly and Company, Indianapolis, Indiana, USA

Authors and Affiliations

  1. Center for Osteoporosis and Metabolic Bone Diseases, Division of Endocrinology and Metabolism, Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, 4301 W. Markham St., Slot #587, Little Rock, AR 72205, USA

    Robert S. Weinstein & A. Michael Parfitt

  2. VA Medical Center, Palo Alto, California, USA

    Robert Marcus

  3. Osteoporosis Medical Center, Palm Desert, California, USA

    Maria Greenwald

  4. Eli Lilly and Company, Indianapolis, Indiana, USA

    Gerald Crans & Douglas B. Muchmore

Authors
  1. Robert S. Weinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Michael Parfitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert Marcus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Greenwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerald Crans
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Douglas B. Muchmore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Weinstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weinstein, R.S., Parfitt, A.M., Marcus, R. et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 14, 814–822 (2003). https://doi.org/10.1007/s00198-003-1434-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1434-z

Keywords

Search

Navigation